Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?

Novo Nordisk (NVO) and Viking Therapeutics (VKTX) have emerged as notable players in the obesity space.A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy (injection) for chronic weight management.On the other hand, Viking Therapeutics is a clinical-stage biotech firm. Its investigational dual GIP and GLP-1 receptor agonist, VK2735, has shown blockbuster potential in early ...